Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Experimental & Molecular Medicine ; : 550-560, 2011.
Artículo en Inglés | WPRIM | ID: wpr-131300

RESUMEN

Protein arginine methylation is important for a variety of cellular processes including transcriptional regulation, mRNA splicing, DNA repair, nuclear/cytoplasmic shuttling and various signal transduction pathways. However, the role of arginine methylation in protein biosynthesis and the extracellular signals that control arginine methylation are not fully understood. Basic fibroblast growth factor (bFGF) has been identified as a potent stimulator of myofibroblast dedifferentiation into fibroblasts. We demonstrated that symmetric arginine dimethylation of eukaryotic elongation factor 2 (eEF2) is induced by bFGF without the change in the expression level of eEF2 in mouse embryo fibroblast NIH3T3 cells. The eEF2 methylation is preceded by ras-raf-mitogen-activated protein kinase kinase (MEK)-extracellular signal-regulated kinase (ERK1/2)-p21(Cip/WAF1) activation, and suppressed by the mitogen-activated protein kinase (MAPK) inhibitor PD98059 and p21(Cip/WAF1) short interfering RNA (siRNA). We determined that protein arginine methyltransferase 7 (PRMT7) is responsible for the methylation, and that PRMT5 acts as a coordinator. Collectively, we demonstrated that eEF2, a key factor involved in protein translational elongation is symmetrically arginine-methylated in a reversible manner, being regulated by bFGF through MAPK signaling pathway.


Asunto(s)
Animales , Ratones , Arginina , Desdiferenciación Celular , Inhibidor p21 de las Quinasas Dependientes de la Ciclina/genética , Quinasa del Factor 2 de Elongación/metabolismo , Factor 2 de Crecimiento de Fibroblastos/metabolismo , Fibroblastos/metabolismo , Flavonoides/farmacología , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Metilación , Proteínas Quinasas Activadas por Mitógenos/antagonistas & inhibidores , Miofibroblastos/patología , Células 3T3 NIH , Proteína Metiltransferasas/metabolismo , Proteína-Arginina N-Metiltransferasas/metabolismo , ARN Interferente Pequeño/genética
2.
Experimental & Molecular Medicine ; : 550-560, 2011.
Artículo en Inglés | WPRIM | ID: wpr-131297

RESUMEN

Protein arginine methylation is important for a variety of cellular processes including transcriptional regulation, mRNA splicing, DNA repair, nuclear/cytoplasmic shuttling and various signal transduction pathways. However, the role of arginine methylation in protein biosynthesis and the extracellular signals that control arginine methylation are not fully understood. Basic fibroblast growth factor (bFGF) has been identified as a potent stimulator of myofibroblast dedifferentiation into fibroblasts. We demonstrated that symmetric arginine dimethylation of eukaryotic elongation factor 2 (eEF2) is induced by bFGF without the change in the expression level of eEF2 in mouse embryo fibroblast NIH3T3 cells. The eEF2 methylation is preceded by ras-raf-mitogen-activated protein kinase kinase (MEK)-extracellular signal-regulated kinase (ERK1/2)-p21(Cip/WAF1) activation, and suppressed by the mitogen-activated protein kinase (MAPK) inhibitor PD98059 and p21(Cip/WAF1) short interfering RNA (siRNA). We determined that protein arginine methyltransferase 7 (PRMT7) is responsible for the methylation, and that PRMT5 acts as a coordinator. Collectively, we demonstrated that eEF2, a key factor involved in protein translational elongation is symmetrically arginine-methylated in a reversible manner, being regulated by bFGF through MAPK signaling pathway.


Asunto(s)
Animales , Ratones , Arginina , Desdiferenciación Celular , Inhibidor p21 de las Quinasas Dependientes de la Ciclina/genética , Quinasa del Factor 2 de Elongación/metabolismo , Factor 2 de Crecimiento de Fibroblastos/metabolismo , Fibroblastos/metabolismo , Flavonoides/farmacología , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Metilación , Proteínas Quinasas Activadas por Mitógenos/antagonistas & inhibidores , Miofibroblastos/patología , Células 3T3 NIH , Proteína Metiltransferasas/metabolismo , Proteína-Arginina N-Metiltransferasas/metabolismo , ARN Interferente Pequeño/genética
3.
Archives of Iranian Medicine. 2010; 13 (3): 235-242
en Inglés | IMEMR | ID: emr-105363

RESUMEN

The incidence of esophageal squamous cell carcinoma [ESCC] is very high in northeastern Iran. However, the genetic predisposing factors to ESCC in this region have not been clearly defined. The P21 [waf1/cip1] gene is involved in the arrest of cellular growth, as induced by the p53 tumor suppressor gene. Two polymorphisms of p21 gene in codon 31 [p21 C98A, dbSNP rs1801270] and the 3'UTR [p21 C70T, dbSNP rs1059234] ma-y affect protein expression and play a role in cancer susceptibility. The present study aimed to investigate the association of p21 polymorphisms in codon 31 and the 3'UTR, and cigarette smoking on the risk of ESCC in northeastern Iran. A case-control study was carried out to detect the p21 polymorphism in the 3'UTR and codon 31 of samples from 126 ESCC cases and 100 controls from 2006 to 2007. There were no significant differences of age and sex between cases and controls. Genotyping of p21 polymorphisms were determined with the PCR-RFLP method. Conditional logistic regression was used to adjust for potential confounders. None of the p21 genotypes were significantly associated with risk of ESCC, even after adjusting for age and gender [P=0.52, OR=1.24; 95%CI: 0.63-2.42]. However, the presence of these polymorphisms in combination with cigarette smoking had a synergistic interaction in ESCC carcinogenesis in northeastern Iran [P=0.02, OR=8.38; 95%CI: 1.03-67.93]. Our data suggests that these two p21 polymorphisms, both alone and in combination, are not genetic susceptibility biomarkers for ESCC. However, their interaction with cigarette smoking may influence the susceptibility to ESCC development in northeastern Iran


Asunto(s)
Humanos , Masculino , Femenino , Inhibidor p21 de las Quinasas Dependientes de la Ciclina/genética , Predisposición Genética a la Enfermedad/epidemiología , Polimorfismo Genético , Fumar/genética , Medición de Riesgo , Polimorfismo de Longitud del Fragmento de Restricción , Modelos Logísticos , Estudios de Casos y Controles , Oportunidad Relativa , Genotipo , Medición de Riesgo , Valores de Referencia
4.
Experimental & Molecular Medicine ; : 429-439, 2009.
Artículo en Inglés | WPRIM | ID: wpr-196694

RESUMEN

Small heterodimer partner (SHP) is an atypical member of nuclear receptor superfamily that lacks a DNA-binding domain. In previous study, we showed that SHP, c-jun, p65 of NF-kappaB subunits, and p21WAF1 expression was increased during monocytic differentiaton with the exposure of human leukemia cells to a differentiation agent, PMA. In this study, c-Jun and p65 were shown to mediate the transcriptional activation of the SHP promoter. In addition, SHP induced the cell cycle regulatory protein levels and cooperatively increased an induction of p21WAF1 expression with p65. Furthermore, SHP protected differentiated cells from etoposide-induced cellular apoptosis through the induction and cytoplasmic sequestration of p21WAF1. Complex formation between SHP and p21WAF1 was demonstrated by means of coimmunoprecipitation. These results suggest that SHP prolongs a cellular survival of differentiating monocytes through the transcriptional regulation of target genes of cell survival and differentiation.


Asunto(s)
Humanos , Apoptosis , Diferenciación Celular , Línea Celular Tumoral , Inhibidor p21 de las Quinasas Dependientes de la Ciclina/genética , Regulación de la Expresión Génica , Monocitos/citología , Regiones Promotoras Genéticas , Proteínas Proto-Oncogénicas c-jun/genética , Receptores Citoplasmáticos y Nucleares/genética , Factor de Transcripción ReIA/genética
5.
Experimental & Molecular Medicine ; : 553-564, 2006.
Artículo en Inglés | WPRIM | ID: wpr-69442

RESUMEN

In cancer gene therapy, restriction of antitumor transgene expression in a radiation field by use of ionizing radiation-inducible promoters is one of the promising approaches for tumor-specific gene delivery. Although tumor suppressor protein p53 is induced by low doses (<1 Gy) of radiation, there have been only a few reports indicating potential utilization of a p53-target gene promoter, such as that of the p21 gene. This is mainly because the transiently transfected promoter of p53-target genes is not much sensitive to radiation. We examined the response of the p21 gene promoter to low-dose radiation when transduced into a human breast cancer cell line MCF-7 by use of recombinant adeno-associated virus (rAAV) vectors. It was shown that the p21 gene promoter transduced by rAAV vectors was more highly radiation-responsive than that transiently transfected by electroporation. A significant induction of the p21 gene promoter by radiation of low doses down to 0.2 Gy was observed. When cells were transduced with the p21 gene promoter-driven HSVtk gene by rAAV vector, they were significantly sensitized to repetitive treatment with low dose radiation (1 Gy) in the presence of the prodrug ganciclovir. It was therefore considered that the p21 gene promoter in combination with a rAAV vector is potentially usable for the development of a low-dose radiation-inducible vector for cancer gene therapy.


Asunto(s)
Humanos , Rayos X , Células Tumorales Cultivadas , Transgenes/efectos de la radiación , Transducción Genética , Regiones Promotoras Genéticas/efectos de la radiación , Vectores Genéticos/efectos de la radiación , Terapia Genética/métodos , Electroporación/métodos , Relación Dosis-Respuesta en la Radiación , Inhibidor p21 de las Quinasas Dependientes de la Ciclina/genética , Adenoviridae , Regiones no Traducidas 3'/fisiología
6.
Experimental & Molecular Medicine ; : 325-331, 2006.
Artículo en Inglés | WPRIM | ID: wpr-51256

RESUMEN

SC-560, a strucutral analogue of celecoxib, induces growth inhibition in a wide range of human cancer cells in a cyclooxygenase (COX)-independent manner. Since SC-560 suppresses the growth of cancer cells mainly by inducing cell cycle arrest, we sought to examine the role of p21CIP1, a cell cycle regulator protein, in the cellular response against SC-560 by using p21(+/+)and p21(-/-)isogenic HCT116 colon carcinoma cells. In HCT116 (p21(+/+)) cells, SC-560 dose-dependently induced growth inhibition and cell cycle arrest at the G1 phase without significant apoptosis induction. SC-560-induced cell cycle arrest was accompanied by upregulation of p21CIP1. However, the extent of SC-560-induced accumulation at the G1 phase was approximately equal in the p21(+/+)and the p21(-/-)cells. Nonetheless, the growth inhibition by SC-560 was increased in p21(-/-)cells than p21(+/+)cells. SC-560-induced reactive oxygen species (ROS) generation did not differ between p21(+/+)and p21(-/-)cells but the subsequent activaton of apoptotic caspase cascade was more pronounced in p21(-/-)cells compared with p21(+/+)cells. These results suggest that p21CIP1 blocks the SC-560-induced apoptotic response of HCT116 cells. SC-560 combined with other therapy that can block p21 CIP1 expression or function may contribute to the effective treatment of colon cancer.


Asunto(s)
Humanos , Especies Reactivas de Oxígeno/metabolismo , Pirazoles/farmacología , Mutación , Immunoblotting , Células HCT116 , Genotipo , Citometría de Flujo , Relación Dosis-Respuesta a Droga , Inhibidores de la Ciclooxigenasa/farmacología , Inhibidor p21 de las Quinasas Dependientes de la Ciclina/genética , Neoplasias del Colon/genética , Supervivencia Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Diferenciación Celular/efectos de los fármacos , Proteínas de Ciclo Celular/metabolismo , Ciclo Celular/efectos de los fármacos , Apoptosis/efectos de los fármacos , Antineoplásicos/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA